Could a COVID shot help fight lung cancer? new trial aims to find out.
NCT ID NCT07597070
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving a Pfizer-BioNTech COVID-19 mRNA vaccine before standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes for people with stage 4 non-small cell lung cancer. Researchers will enroll 500 adults to see if the vaccine helps the immune system attack the cancer more effectively. The main goal is to check for serious side effects, but they will also measure how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pfizer-BioNTech mRNA COVID-19 vaccine
- What this could lead to
- If it works, this could offer a simple, widely available way to make immunotherapy more effective for more people with advanced lung cancer.
- What could go wrong
- This is a Phase 2 trial, so it's still early. The vaccine might not improve outcomes and could increase immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN) STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.